Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Journal of Biochemistry|June 24, 2004
Functions of MAP kinases: insights from gene-targeting studiesKeisuke Kuida, Diane M BoucherCurrent Opinion in Pharmacology|July 16, 2010
Cancer stem cells as the relevant biomass for drug discoveryRaymond J Winquist, Brinley F Furey, Diane M BoucherBiochemical Pharmacology|June 23, 2009
Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engineRaymond J Winquist, Diane M Boucher, Mark Wood, et al.Proceedings of the National Academy of Sciences of the United States of America|July 3, 2002
Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defectsChristopher P Regan, Wei Li, Diane M Boucher, et al.Proceedings of the National Academy of Sciences of the United States of America|October 21, 2003
Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiationYao Yao, Wei Li, Junwei Wu, et al.Journal of Pharmaceutical Sciences|November 7, 2017
Proof of Principle for Local Delivery of a c-Met InhibitorHoward Li, Irina Kadiyala, Michael Briggs, et al.Biomaterials|March 31, 2015
A paper-based invasion assay: assessing chemotaxis of cancer cells in gradients of oxygenBobak Mosadegh, Matthew R Lockett, Kyaw Thu Minn, et al.Biomaterials|April 27, 2016
Metabolic response of lung cancer cells to radiation in a paper-based 3D cell culture systemKaren A Simon, Bobak Mosadegh, Kyaw Thu Minn, et al.Oncotarget|July 11, 2014
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970Amy B Hall, Dave Newsome, Yuxin Wang, et al.Molecular Cancer Therapeutics|September 24, 2017
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)Ursula A Germann, Brinley F Furey, William Markland, et al.Pageof 1